Baseline characteristics

LUX Lung 2 Phase II Single Arm BIBW 2992 "Afatinib" in NSCLC With EGFR Activating Mutations · Source last updated 2016-09-16

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

denoms

1. counts

   1. group Id

      BG000

      value

      23

   2. group Id

      BG001

      value

      38

   3. group Id

      BG002

      value

      7

   4. group Id

      BG003

      value

      61

   5. group Id

      BG004

      value

      129

   units

   Participants

groups

1. description

   First-line patients were enrolled after Amendment 1 with a starting oral dose of Afatinib 40 mg daily after Amendment 2. Dose reduction scheme was defined for patients unable to tolerate this dose.

   id

   BG000

   title

   First-line Afatinib 40 mg

2. description

   First-line patients were enrolled after Amendment 1 with a starting oral dose of Afatinib 50 mg daily. Dose reduction scheme was defined for patients unable to tolerate this dose.

   id

   BG001

   title

   First-line Afatinib 50 mg

3. description

   Second-line patients received a starting oral dose of Afatinib 40 mg daily only after Amendment 2. Dose reduction scheme was defined for patients unable to tolerate this dose.

   id

   BG002

   title

   Second-line Afatinib 40 mg

4. description

   Second-line patients received a starting oral dose of Afatinib 50 mg daily. Dose reduction scheme was defined for patients unable to tolerate this dose.

   id

   BG003

   title

   Second-line Afatinib 50 mg

5. description

   Total of all reporting groups

   id

   BG004

   title

   Total

measures

1. classes

   1. categories

      1. measurements

         1. group Id

            BG000

            spread

            11.0

            value

            64

         2. group Id

            BG001

            spread

            9.6

            value

            62

         3. group Id

            BG002

            spread

            14.5

            value

            57

         4. group Id

            BG003

            spread

            11.5

            value

            61

         5. group Id

            BG004

            spread

            11.1

            value

            62

   dispersion Type

   STANDARD_DEVIATION

   param Type

   MEAN

   title

   Age, Continuous

   unit Of Measure

   years

2. classes

   1. categories

      1. measurements

         1. group Id

            BG000

            value

            13

         2. group Id

            BG001

            value

            27

         3. group Id

            BG002

            value

            3

         4. group Id

            BG003

            value

            32

         5. group Id

            BG004

            value

            75

         title

         Female

      2. measurements

         1. group Id

            BG000

            value

            10

         2. group Id

            BG001

            value

            11

         3. group Id

            BG002

            value

            4

         4. group Id

            BG003

            value

            29

         5. group Id

            BG004

            value

            54

         title

         Male

   param Type

   COUNT_OF_PARTICIPANTS

   title

   Sex: Female, Male

   unit Of Measure

   Participants

population Description

Treated set: The patients who had taken at least one dose of afatinib were included in the treated set.

Download exact source JSON → · Snapshot ctgov-results-191f4516d4760045304b24a0

Preserved source evidence · Not medical advice